Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02229877
Recruitment Status : Completed
First Posted : September 3, 2014
Last Update Posted : April 18, 2017
Sponsor:
Collaborator:
Celerion
Information provided by (Responsible Party):
Afferent Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to: determine the effect of stomach pH on the multiple dose pharmacokinetics (PK) of gefapixant (AF-219); assess the effect of multiple doses of gefapixant on various sensory assessments; and, assess the safety and tolerability of gefapixant.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Omeprazole Drug: Gefapixant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219
Actual Study Start Date : October 31, 2014
Actual Primary Completion Date : May 31, 2015
Actual Study Completion Date : May 31, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Gefapixant + Omeprazole

Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days

+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days

Drug: Omeprazole
40 mg oral capsules administered twice daily for 8.5 days
Other Name: Prilosec

Drug: Gefapixant
Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
Other Names:
  • AF-219
  • MK-7264

Drug: Gefapixant
Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
Other Names:
  • AF-219
  • MK-7264

Drug: Gefapixant
Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
Other Names:
  • AF-219
  • MK-7264




Primary Outcome Measures :
  1. Effect of Intragastric pH on gefapixant PK [ Time Frame: At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose ]
    Analysis of variance (ANOVA) will be performed on log normal-transformed Cmax and AUC0-t values to determine the extent of a drug interaction, if any, of omeprazole on the plasma gefapixant PK parameters. These analyses will be conducted for both fed and fasted conditions and the 50 mg and 150 mg treatments.


Secondary Outcome Measures :
  1. Effect of Fasting on gefapixant PK [ Time Frame: At pre-dose (time 0) and at 1, 2, 3, 5, 8, and 12 hours post dose ]
    ANOVA will be performed on log normal-transformed Cmax and AUC0-t values to determine if fasting affects plasma gefapixant PK parameters.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Must be informed of the nature of the study and have provided written informed voluntary consent;

Able to speak, read, and understand English;

Healthy males or females, of any race, between 18 and 55 years of age, inclusive;

Body mass index (BMI) >18.5 and <32.0 kg/m2 and weigh 50 - 100 kg;

In good general health ;

Non-smokers for at least 5 years;

If a female of child-bearing potential (i.e., have not undergone a hysterectomy or bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12 months), agree to use 2 forms of acceptable birth control; or if a male, they and/or their partner of child-bearing potential agree to use 2 forms of acceptable birth control;

Exclusion Criteria:

Any disease or condition that might affect drug absorption, metabolism, or excretion or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease;

Clinically significant illness or clinically significant surgery within 4 weeks before the administration of study medication;

Any past sinus surgery, upper respiratory tract infection within 2 weeks before dosing, or history of hay fever during the time of the year that dosing will be taking place;

History of GERD, heartburn, or nausea more than once a month, or any similar symptoms requiring the regular use of antacids, or any use of H2 histamine blockers or proton pump inhibitors within 12 months of Screening;

Have a positive screening test for Helicobacter pylori;

QTcB >450 msec in males or >460 msec in females;

Known or suspected hypersensitivity or allergic reaction to any of the components of gefapixant or omeprazole capsules;

If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose;

Blood loss or blood donation of >550 mL within 90 days or plasma donation >500 mL within 14 days before administration of the first dose of study drug;

Chronic use of any systemic medications; use of a drug therapy known to induce or inhibit hepatic drug metabolism within 30 days before the first dose of study medication; or use of any medications including antacids, high dose multivitamins, nutritional supplements, and herbal preparations, within 14 days before the first dose of study drug;

Past or current history or evidence of drug or alcohol abuse, use of any recreational soft drugs (e.g., marijuana) within 3 months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and crack) within 1 year of screening, and/or a positive screen for substances of abuse or alcohol at screening or pre dose;

Ingestion of grapefruit or grapefruit juice within 48 hours before dose administration;

Positive urine cotinine test at Screening or Day 1 pre dose;

Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody;

Receipt of an investigational product or device, or participation in a drug research study within a period of 30 days (or 5 half lives of the drug, whichever is longer) before the first dose of study medication;

Receipt of an investigational immunomodulator or monoclonal antibody within 180 days (or 5 half lives, whichever is longer) before the first dose of study medication


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02229877


Locations
Layout table for location information
United States, Arizona
Celerion
Tempe, Arizona, United States, 85283
Sponsors and Collaborators
Afferent Pharmaceuticals, Inc.
Celerion
Investigators
Layout table for investigator information
Principal Investigator: Terry O'Reilly, M.D. Celerion

Layout table for additonal information
Responsible Party: Afferent Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02229877     History of Changes
Other Study ID Numbers: 7264-011
AF219-011 ( Other Identifier: Afferent Pharmaceuticals )
First Posted: September 3, 2014    Key Record Dates
Last Update Posted: April 18, 2017
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Omeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action